Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Sunitinib maleate
DRUG
2 trials
Sponsors
Kidney Cancer Research Bureau
, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Anlotinib
Carcinoma, Renal Cell
RCC
Phase 1
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
Completed
NCT00891475
Kidney Cancer Research Bureau
Carcinoma, Renal Cell
Start: 2008-05-31
End: 2011-01-31
Updated: 2014-02-13
Phase 2
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
NCT02072031
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anlotinib, RCC
Start: 2013-12-31
End: 2016-12-31
Target: 133
Updated: 2016-04-26
Related Papers
Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
PLoS ONE
2023-02-07
6 citations
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
Frontiers in Oncology
2020-05-07
33 citations
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
Journal of Clinical Oncology
2016-05-20
11 citations